Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. November 2015 11:50 ET | Quelle: ThromboGenics NV

ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA(r) (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole

Importance of proper patient selection demonstrated No new safety signals identified, majority of adverse events resolve LEUVEN, Belgium, Nov. 18, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV...
12. November 2015 01:35 ET | Quelle: ThromboGenics NV

ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA(r) for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)

ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy...
23. April 2015 01:36 ET | Quelle: ThromboGenics NV

ThromboGenics Starts Evaluating JETREA(r) for the Treatment of Retinal Vein Occlusion (RVO)

LEUVEN, Belgium, April 23, 2015 (GLOBE NEWSWIRE) -- Company receives € 0.6 million research grant from IWT, the Flemish Agency for Innovation by Science and Technology ThromboGenics NV...
16. März 2015 02:05 ET | Quelle: ThromboGenics NV

ThromboGenics' JETREA(r) Gains Approval in Brazil

LEUVEN, Belgium, March 16, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
02. März 2015 11:55 ET | Quelle: ThromboGenics NV

ThromboGenics Receives Positive CHMP Opinion for Ready Diluted Formulation of JETREA(r)

LEUVEN, Belgium, March 2, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
05. Februar 2015 02:06 ET | Quelle: ThromboGenics NV

Thrombogenics Awarded EU1.1 million IWT Research Grant

LEUVEN, Belgium, Feb. 5, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
22. Januar 2015 04:02 ET | Quelle: ThromboGenics NV

ThromboGenics Appoints Emmanuele Attout as Independent Non-Executive Director

LEUVEN, Belgium, Jan. 22, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
08. September 2014 01:54 ET | Quelle: ThromboGenics NV

ThromboGenics' JETREA(R) Gains Approval in South Korea

LEUVEN, Belgium, Sept. 8, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
29. April 2014 01:40 ET | Quelle: ThromboGenics NV

ThromboGenics Activates 50th Retina Center for its US Observational Patient Trial with JETREA(R) (ORBIT)

LEUVEN, Belgium, April 29, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
17. März 2014 12:55 ET | Quelle: ThromboGenics NV

ThromboGenics Announces Business Update and 2013 Full-Year Results

REGULATED INFORMATION JETREA ® in the US US sales of JETREA® were €20.2 million in 2013, with close to 7000 patients treated In the second half of 2013, the Company...